|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, miR-141-3p inhibitor partially reversed the observed SNHG15 depletion-mediated reduction in HCC proliferation, migration, and invasion.
|
31310393 |
2019 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MiR-141-3p overexpression significantly decreased HCC cell proliferation, migration, and invasion by inhibiting epithelial-mesenchymal transition (EMT).
|
30695725 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Integrated analysis of circRNA-100338, miR-141-3p, and target genes revealed that RHEB, a key regulator in mTOR signaling pathway, was the target of miR-141-3p in hepatitis B-related HCC.
|
31157168 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
miR‑141 inhibits proliferation, migration and invasion in human hepatocellular carcinoma cells by directly downregulating TGFβR1.
|
31545479 |
2019 |
|
Liver carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
ELF3 promotes epithelial-mesenchymal transition by protecting ZEB1 from miR-141-3p-mediated silencing in hepatocellular carcinoma.
|
29523781 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>In vivo</i> tumor-suppressive effects of miR-141 on HCC were examined in mice upon intratumoral injection of miR-141:NPX-glue.
|
30083268 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, our study is the first to demonstrate that lower expression of KRAL, a long non-coding RNA (lncRNA), mediates 5-FU resistance in HCC via the miR-141/Keap1 axis.
|
30119680 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Real-time quantitative polymerase chain reaction confirmed a similar trend of decreased miR-141-3p in hepatocellular carcinoma tissue (1.7542 [0.8663] vs 2.5562 [1.7913], P = .001) as observed in The Cancer Genome Atlas.
|
28436261 |
2017 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, circRNA_100338 functions as an endogenous sponge for miR-141-3p in HCC.
|
28710406 |
2017 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
An inverse correlation was observed between SPAG9 and miR-141 expression in HCC tissues and cell lines.
|
26790956 |
2016 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
miR-141 is one of the miRNAs that has significant expression variations in different human malignancies including prostate cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, gastric cancer, and ovarian cancer.
|
25789530 |
2016 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Up-regulation of miR-141 expression resulted in a significant inhibition of 5-FU-mediated cytotoxicity and apoptosis in various hepatocellular carcinoma cells-lines.
|
25896253 |
2015 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cell proliferation, invasion, and apoptosis were also examined to confirm whether miR-141 could impact on HNF-3β in HCC.
|
25425543 |
2014 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, we identified zinc finger E-box binding homeobox 2 (ZEB2) as a target of miR-141 and miR-141 functioned as a tumor suppressor via ZEB2 targeting in HCC.
|
25008569 |
2014 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, multivariate Cox regression analysis indicated that miR-141 could serve as an independent prognostic factor in HCC.
|
24551096 |
2014 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Decreased expression of miR-141 was observed in both HCC tissues and cell lines.
|
25142234 |
2014 |